Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Idiopathic Pulmonary Fibrosis (IPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

Idiopathic Pulmonary Fibrosis (IPF) market is currently driven by factors such as a rising geriatric population, cigarette smoking, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates.  Idiopathic Pulmonary Fibrosis represents the most common of the idiopathic interstitial pneumonias and is characterized by a chronic, progressive, fibrotic interstitial lung disease having an unknown cause. This disease rarely occurs before the age of 50 years and primarily affects older adults (60+). With the geriatric population expected to increase considerably over the long term, we expect the incidence of Idiopathic Pulmonary Fibrosis to increase significantly over the next few years.

In patients with IPF, the tiny air sacs in the lungs (alveoli) get damaged and increasingly scarred. This results in the lungs becoming stiff that makes it hard for oxygen to get into the blood. The causes of IPF are unknown, but various risk factors have been identified, this includes older age, cigarette smoking, environmental exposures, certain infections, etc. Cigarette smoking, particularly involving more than 20 pack-years, represents the most strongly associated environmental risk factor. Furthermore, heightened risk for IPF has been associated with various environmental exposures (metal dusts, automobile emissions, and wood dust). Occupations such as agriculture and managing livestock have also been associated with IPF.  There is a high unmet need for novel therapies to treat IPF as conventional drugs has limited efficacy or an unfavorable safety profile.

IMARC Group’s new report "Idiopathic Pulmonary Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Idiopathic Pulmonary Fibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Idiopathic Pulmonary Fibrosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Idiopathic Pulmonary Fibrosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Idiopathic Pulmonary Fibrosis and represents the largest market for Idiopathic Pulmonary Fibrosis treatment. Furthermore, the current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Idiopathic Pulmonary Fibrosis market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current, and Future Epidemiology Scenario
  • Historical, Current, and Future Performance of the Idiopathic Pulmonary Fibrosis Market
  • Historical, Current, and Future Performance of Various Therapeutic Categories in the Idiopathic Pulmonary Fibrosis Market
  • Sales of Various Drugs Across the Idiopathic Pulmonary Fibrosis Market
  • Reimbursement Scenario in the Idiopathic Pulmonary Fibrosis Market
     

Idiopathic Pulmonary Fibrosis: In-Market and Pipeline Drugs

This report also provides a detailed analysis of the current Idiopathic Pulmonary Fibrosis marketed drugs and late-stage pipeline drugs.

  • In-Market Idiopathic Pulmonary Fibrosis Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Idiopathic Pulmonary Fibrosis Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status
       

Key Questions Answered in this Report

Market Insights

  • How has the Idiopathic Pulmonary Fibrosis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Idiopathic Pulmonary Fibrosis market across the seven major markets in 2021 and what will it look like in 2032?
  • What is the growth rate of the Idiopathic Pulmonary Fibrosis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Idiopathic Pulmonary Fibrosis market?

 

Epidemiology Insights

  • What is the size of the Idiopathic Pulmonary Fibrosis patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Idiopathic Pulmonary Fibrosis across the seven major markets?
  • What are the key factors driving the epidemiological trend of Idiopathic Pulmonary Fibrosis?
  • What will be the growth rate of Idiopathic Pulmonary Fibrosis patients across the seven major markets?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current marketed Idiopathic Pulmonary Fibrosis drugs and what are their market performance?
  • What are the key pipeline Idiopathic Pulmonary Fibrosis drugs and how are they expected to perform in the coming years?
  • How safe are the currently marketed Idiopathic Pulmonary Fibrosis drugs and what are their efficacies?
  • How safe are the late-stage pipeline Idiopathic Pulmonary Fibrosis drugs and what are their efficacies?
  • What are the current treatment guidelines for Idiopathic Pulmonary Fibrosis drugs across the seven major markets?
  • Who are the key companies in the Idiopathic Pulmonary Fibrosis market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Idiopathic Pulmonary Fibrosis market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Idiopathic Pulmonary Fibrosis - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Idiopathic Pulmonary Fibrosis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Idiopathic Pulmonary Fibrosis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Idiopathic Pulmonary Fibrosis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Idiopathic Pulmonary Fibrosis Guidelines, Management and Treatment
8.2 Idiopathic Pulmonary Fibrosis Treatment Algorithm

9 Idiopathic Pulmonary Fibrosis - Unmet Needs

10 Idiopathic Pulmonary Fibrosis - Key Endpoints of Treatment

11 Idiopathic Pulmonary Fibrosis - Marketed Products
11.1 List of Idiopathic Pulmonary Fibrosis Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12 Idiopathic Pulmonary Fibrosis - Pipeline Drugs
12.1 List of Idiopathic Pulmonary Fibrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

13. Idiopathic Pulmonary Fibrosis - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Idiopathic Pulmonary Fibrosis - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Idiopathic Pulmonary Fibrosis - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Idiopathic Pulmonary Fibrosis - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Idiopathic Pulmonary Fibrosis - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Idiopathic Pulmonary Fibrosis - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Idiopathic Pulmonary Fibrosis - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Idiopathic Pulmonary Fibrosis - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Idiopathic Pulmonary Fibrosis - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Idiopathic Pulmonary Fibrosis  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Idiopathic Pulmonary Fibrosis - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Idiopathic Pulmonary Fibrosis - Access and Reimbursement Overview

15 Idiopathic Pulmonary Fibrosis - Recent Events and Inputs From Key Opinion Leaders

16 Idiopathic Pulmonary Fibrosis Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4